

# COVID-19 Impact on Global Parkinsons disease Drug Market Insights, Forecast to 2026

<https://marketpublishers.com/r/CBA090596847EN.html>

Date: August 2020

Pages: 118

Price: US\$ 3,900.00 (Single User License)

ID: CBA090596847EN

## Abstracts

Parkinsons disease Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Parkinsons disease Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Parkinsons disease Drug market is segmented into

Carbidopa/Levodopa

Dopamine Receptor Agonists

MAO-Inhibitors

Segment by Application, the Parkinsons disease Drug market is segmented into

Hospital

Online

Retail Pharmacies

Regional and Country-level Analysis

The Parkinsons disease Drug market is analysed and market size information is provided by regions (countries).

The key regions covered in the Parkinsons disease Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

**Competitive Landscape and Parkinsons disease Drug Market Share Analysis**  
Parkinsons disease Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Parkinsons disease Drug business, the date to enter into the Parkinsons disease Drug market, Parkinsons disease Drug product introduction, recent developments, etc.

The major vendors covered:

Teva

Novartis AG

GSK

AbbVie

Merck

Boehringer Ingelheim

Impax Laboratories

Lundbeck

Sun Pharma

Wockhardt

UCB

Bausch Health

Acadia

## Contents

### 1 STUDY COVERAGE

- 1.1 Parkinsons disease Drug Product Introduction
- 1.2 Market Segments
- 1.3 Key Parkinsons disease Drug Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
  - 1.4.1 Global Parkinsons disease Drug Market Size Growth Rate by Type
  - 1.4.2 Carbidopa/Levodopa
  - 1.4.3 Dopamine Receptor Agonists
  - 1.4.4 MAO-Inhibitors
- 1.5 Market by Application
  - 1.5.1 Global Parkinsons disease Drug Market Size Growth Rate by Application
  - 1.5.2 Hospital
  - 1.5.3 Online
  - 1.5.4 Retail Pharmacies
- 1.6 Coronavirus Disease 2019 (Covid-19): Parkinsons disease Drug Industry Impact
  - 1.6.1 How the Covid-19 is Affecting the Parkinsons disease Drug Industry
    - 1.6.1.1 Parkinsons disease Drug Business Impact Assessment - Covid-19
    - 1.6.1.2 Supply Chain Challenges
    - 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
  - 1.6.2 Market Trends and Parkinsons disease Drug Potential Opportunities in the COVID-19 Landscape
  - 1.6.3 Measures / Proposal against Covid-19
    - 1.6.3.1 Government Measures to Combat Covid-19 Impact
    - 1.6.3.2 Proposal for Parkinsons disease Drug Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

### 2 EXECUTIVE SUMMARY

- 2.1 Global Parkinsons disease Drug Market Size Estimates and Forecasts
  - 2.1.1 Global Parkinsons disease Drug Revenue 2015-2026
  - 2.1.2 Global Parkinsons disease Drug Sales 2015-2026
- 2.2 Parkinsons disease Drug Market Size by Region: 2020 Versus 2026
  - 2.2.1 Global Parkinsons disease Drug Retrospective Market Scenario in Sales by Region: 2015-2020
  - 2.2.2 Global Parkinsons disease Drug Retrospective Market Scenario in Revenue by

Region: 2015-2020

### **3 GLOBAL PARKINSONS DISEASE DRUG COMPETITOR LANDSCAPE BY PLAYERS**

#### 3.1 Parkinsons disease Drug Sales by Manufacturers

3.1.1 Parkinsons disease Drug Sales by Manufacturers (2015-2020)

3.1.2 Parkinsons disease Drug Sales Market Share by Manufacturers (2015-2020)

#### 3.2 Parkinsons disease Drug Revenue by Manufacturers

3.2.1 Parkinsons disease Drug Revenue by Manufacturers (2015-2020)

3.2.2 Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)

3.2.3 Global Parkinsons disease Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)

3.2.4 Global Top 10 and Top 5 Companies by Parkinsons disease Drug Revenue in 2019

3.2.5 Global Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

#### 3.3 Parkinsons disease Drug Price by Manufacturers

#### 3.4 Parkinsons disease Drug Manufacturing Base Distribution, Product Types

3.4.1 Parkinsons disease Drug Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers Parkinsons disease Drug Product Type

3.4.3 Date of International Manufacturers Enter into Parkinsons disease Drug Market

#### 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

### **4 BREAKDOWN DATA BY TYPE (2015-2026)**

#### 4.1 Global Parkinsons disease Drug Market Size by Type (2015-2020)

4.1.1 Global Parkinsons disease Drug Sales by Type (2015-2020)

4.1.2 Global Parkinsons disease Drug Revenue by Type (2015-2020)

4.1.3 Parkinsons disease Drug Average Selling Price (ASP) by Type (2015-2026)

#### 4.2 Global Parkinsons disease Drug Market Size Forecast by Type (2021-2026)

4.2.1 Global Parkinsons disease Drug Sales Forecast by Type (2021-2026)

4.2.2 Global Parkinsons disease Drug Revenue Forecast by Type (2021-2026)

4.2.3 Parkinsons disease Drug Average Selling Price (ASP) Forecast by Type (2021-2026)

4.3 Global Parkinsons disease Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

## **5 BREAKDOWN DATA BY APPLICATION (2015-2026)**

### 5.1 Global Parkinsons disease Drug Market Size by Application (2015-2020)

#### 5.1.1 Global Parkinsons disease Drug Sales by Application (2015-2020)

#### 5.1.2 Global Parkinsons disease Drug Revenue by Application (2015-2020)

#### 5.1.3 Parkinsons disease Drug Price by Application (2015-2020)

### 5.2 Parkinsons disease Drug Market Size Forecast by Application (2021-2026)

#### 5.2.1 Global Parkinsons disease Drug Sales Forecast by Application (2021-2026)

#### 5.2.2 Global Parkinsons disease Drug Revenue Forecast by Application (2021-2026)

#### 5.2.3 Global Parkinsons disease Drug Price Forecast by Application (2021-2026)

## **6 NORTH AMERICA**

### 6.1 North America Parkinsons disease Drug by Country

#### 6.1.1 North America Parkinsons disease Drug Sales by Country

#### 6.1.2 North America Parkinsons disease Drug Revenue by Country

#### 6.1.3 U.S.

#### 6.1.4 Canada

### 6.2 North America Parkinsons disease Drug Market Facts & Figures by Type

### 6.3 North America Parkinsons disease Drug Market Facts & Figures by Application

## **7 EUROPE**

### 7.1 Europe Parkinsons disease Drug by Country

#### 7.1.1 Europe Parkinsons disease Drug Sales by Country

#### 7.1.2 Europe Parkinsons disease Drug Revenue by Country

#### 7.1.3 Germany

#### 7.1.4 France

#### 7.1.5 U.K.

#### 7.1.6 Italy

#### 7.1.7 Russia

### 7.2 Europe Parkinsons disease Drug Market Facts & Figures by Type

### 7.3 Europe Parkinsons disease Drug Market Facts & Figures by Application

## **8 ASIA PACIFIC**

### 8.1 Asia Pacific Parkinsons disease Drug by Region

#### 8.1.1 Asia Pacific Parkinsons disease Drug Sales by Region

#### 8.1.2 Asia Pacific Parkinsons disease Drug Revenue by Region

- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam

8.2 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Type

8.3 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Application

## **9 LATIN AMERICA**

9.1 Latin America Parkinsons disease Drug by Country

- 9.1.1 Latin America Parkinsons disease Drug Sales by Country
- 9.1.2 Latin America Parkinsons disease Drug Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina

9.2 Central & South America Parkinsons disease Drug Market Facts & Figures by Type

9.3 Central & South America Parkinsons disease Drug Market Facts & Figures by Application

## **10 MIDDLE EAST AND AFRICA**

10.1 Middle East and Africa Parkinsons disease Drug by Country

- 10.1.1 Middle East and Africa Parkinsons disease Drug Sales by Country
- 10.1.2 Middle East and Africa Parkinsons disease Drug Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E

10.2 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Type

10.3 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Application

## **11 COMPANY PROFILES**

## 11.1 Teva

11.1.1 Teva Corporation Information

11.1.2 Teva Description, Business Overview and Total Revenue

11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)

11.1.4 Teva Parkinsons disease Drug Products Offered

11.1.5 Teva Recent Development

## 11.2 Novartis AG

11.2.1 Novartis AG Corporation Information

11.2.2 Novartis AG Description, Business Overview and Total Revenue

11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)

11.2.4 Novartis AG Parkinsons disease Drug Products Offered

11.2.5 Novartis AG Recent Development

## 11.3 GSK

11.3.1 GSK Corporation Information

11.3.2 GSK Description, Business Overview and Total Revenue

11.3.3 GSK Sales, Revenue and Gross Margin (2015-2020)

11.3.4 GSK Parkinsons disease Drug Products Offered

11.3.5 GSK Recent Development

## 11.4 AbbVie

11.4.1 AbbVie Corporation Information

11.4.2 AbbVie Description, Business Overview and Total Revenue

11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)

11.4.4 AbbVie Parkinsons disease Drug Products Offered

11.4.5 AbbVie Recent Development

## 11.5 Merck

11.5.1 Merck Corporation Information

11.5.2 Merck Description, Business Overview and Total Revenue

11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)

11.5.4 Merck Parkinsons disease Drug Products Offered

11.5.5 Merck Recent Development

## 11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Corporation Information

11.6.2 Boehringer Ingelheim Description, Business Overview and Total Revenue

11.6.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)

11.6.4 Boehringer Ingelheim Parkinsons disease Drug Products Offered

11.6.5 Boehringer Ingelheim Recent Development

## 11.7 Impax Laboratories

11.7.1 Impax Laboratories Corporation Information



- 11.7.2 Impax Laboratories Description, Business Overview and Total Revenue
- 11.7.3 Impax Laboratories Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 Impax Laboratories Parkinsons disease Drug Products Offered
- 11.7.5 Impax Laboratories Recent Development
- 11.8 Lundbeck
  - 11.8.1 Lundbeck Corporation Information
  - 11.8.2 Lundbeck Description, Business Overview and Total Revenue
  - 11.8.3 Lundbeck Sales, Revenue and Gross Margin (2015-2020)
  - 11.8.4 Lundbeck Parkinsons disease Drug Products Offered
  - 11.8.5 Lundbeck Recent Development
- 11.9 Sun Pharma
  - 11.9.1 Sun Pharma Corporation Information
  - 11.9.2 Sun Pharma Description, Business Overview and Total Revenue
  - 11.9.3 Sun Pharma Sales, Revenue and Gross Margin (2015-2020)
  - 11.9.4 Sun Pharma Parkinsons disease Drug Products Offered
  - 11.9.5 Sun Pharma Recent Development
- 11.10 Wockhardt
  - 11.10.1 Wockhardt Corporation Information
  - 11.10.2 Wockhardt Description, Business Overview and Total Revenue
  - 11.10.3 Wockhardt Sales, Revenue and Gross Margin (2015-2020)
  - 11.10.4 Wockhardt Parkinsons disease Drug Products Offered
  - 11.10.5 Wockhardt Recent Development
- 11.1 Teva
  - 11.1.1 Teva Corporation Information
  - 11.1.2 Teva Description, Business Overview and Total Revenue
  - 11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
  - 11.1.4 Teva Parkinsons disease Drug Products Offered
  - 11.1.5 Teva Recent Development
- 11.12 Bausch Health
  - 11.12.1 Bausch Health Corporation Information
  - 11.12.2 Bausch Health Description, Business Overview and Total Revenue
  - 11.12.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
  - 11.12.4 Bausch Health Products Offered
  - 11.12.5 Bausch Health Recent Development
- 11.13 Acadia
  - 11.13.1 Acadia Corporation Information
  - 11.13.2 Acadia Description, Business Overview and Total Revenue
  - 11.13.3 Acadia Sales, Revenue and Gross Margin (2015-2020)
  - 11.13.4 Acadia Products Offered

### 11.13.5 Acadia Recent Development

## **12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)**

### 12.1 Parkinsons disease Drug Market Estimates and Projections by Region

12.1.1 Global Parkinsons disease Drug Sales Forecast by Regions 2021-2026

12.1.2 Global Parkinsons disease Drug Revenue Forecast by Regions 2021-2026

### 12.2 North America Parkinsons disease Drug Market Size Forecast (2021-2026)

12.2.1 North America: Parkinsons disease Drug Sales Forecast (2021-2026)

12.2.2 North America: Parkinsons disease Drug Revenue Forecast (2021-2026)

12.2.3 North America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)

### 12.3 Europe Parkinsons disease Drug Market Size Forecast (2021-2026)

12.3.1 Europe: Parkinsons disease Drug Sales Forecast (2021-2026)

12.3.2 Europe: Parkinsons disease Drug Revenue Forecast (2021-2026)

12.3.3 Europe: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)

### 12.4 Asia Pacific Parkinsons disease Drug Market Size Forecast (2021-2026)

12.4.1 Asia Pacific: Parkinsons disease Drug Sales Forecast (2021-2026)

12.4.2 Asia Pacific: Parkinsons disease Drug Revenue Forecast (2021-2026)

12.4.3 Asia Pacific: Parkinsons disease Drug Market Size Forecast by Region (2021-2026)

### 12.5 Latin America Parkinsons disease Drug Market Size Forecast (2021-2026)

12.5.1 Latin America: Parkinsons disease Drug Sales Forecast (2021-2026)

12.5.2 Latin America: Parkinsons disease Drug Revenue Forecast (2021-2026)

12.5.3 Latin America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)

### 12.6 Middle East and Africa Parkinsons disease Drug Market Size Forecast (2021-2026)

12.6.1 Middle East and Africa: Parkinsons disease Drug Sales Forecast (2021-2026)

12.6.2 Middle East and Africa: Parkinsons disease Drug Revenue Forecast (2021-2026)

12.6.3 Middle East and Africa: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)

## **13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS**

### 13.1 Market Opportunities and Drivers

13.2 Market Challenges

13.3 Market Risks/Restraints

13.4 Porter's Five Forces Analysis

13.5 Primary Interviews with Key Parkinsons disease Drug Players (Opinion Leaders)

## **14 VALUE CHAIN AND SALES CHANNELS ANALYSIS**

14.1 Value Chain Analysis

14.2 Parkinsons disease Drug Customers

14.3 Sales Channels Analysis

14.3.1 Sales Channels

14.3.2 Distributors

## **15 RESEARCH FINDINGS AND CONCLUSION**

## **16 APPENDIX**

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.2 Data Source

16.2 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Parkinsons disease Drug Market Segments

Table 2. Ranking of Global Top Parkinsons disease Drug Manufacturers by Revenue (US\$ Million) in 2019

Table 3. Global Parkinsons disease Drug Market Size Growth Rate by Type 2020-2026 (K Doses) & (US\$ Million)

Table 4. Major Manufacturers of Carbidopa/Levodopa

Table 5. Major Manufacturers of Dopamine Receptor Agonists

Table 6. Major Manufacturers of MAO-Inhibitors

Table 7. COVID-19 Impact Global Market: (Four Parkinsons disease Drug Market Size Forecast Scenarios)

Table 8. Opportunities and Trends for Parkinsons disease Drug Players in the COVID-19 Landscape

Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 10. Key Regions/Countries Measures against Covid-19 Impact

Table 11. Proposal for Parkinsons disease Drug Players to Combat Covid-19 Impact

Table 12. Global Parkinsons disease Drug Market Size Growth Rate by Application 2020-2026 (K Doses)

Table 13. Global Parkinsons disease Drug Market Size by Region (K Doses) & (US\$ Million): 2020 VS 2026

Table 14. Global Parkinsons disease Drug Sales by Regions 2015-2020 (K Doses)

Table 15. Global Parkinsons disease Drug Sales Market Share by Regions (2015-2020)

Table 16. Global Parkinsons disease Drug Revenue by Regions 2015-2020 (US\$ Million)

Table 17. Global Parkinsons disease Drug Sales by Manufacturers (2015-2020) (K Doses)

Table 18. Global Parkinsons disease Drug Sales Share by Manufacturers (2015-2020)

Table 19. Global Parkinsons disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 20. Global Parkinsons disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinsons disease Drug as of 2019)

Table 21. Parkinsons disease Drug Revenue by Manufacturers (2015-2020) (US\$ Million)

Table 22. Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)

Table 23. Key Manufacturers Parkinsons disease Drug Price (2015-2020) (USD/Dose)

Table 24. Parkinsons disease Drug Manufacturers Manufacturing Base Distribution and

## Headquarters

Table 25. Manufacturers Parkinsons disease Drug Product Type

Table 26. Date of International Manufacturers Enter into Parkinsons disease Drug Market

Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 28. Global Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)

Table 29. Global Parkinsons disease Drug Sales Share by Type (2015-2020)

Table 30. Global Parkinsons disease Drug Revenue by Type (2015-2020) (US\$ Million)

Table 31. Global Parkinsons disease Drug Revenue Share by Type (2015-2020)

Table 32. Parkinsons disease Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Dose)

Table 33. Global Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)

Table 34. Global Parkinsons disease Drug Sales Share by Application (2015-2020)

Table 35. North America Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)

Table 36. North America Parkinsons disease Drug Sales Market Share by Country (2015-2020)

Table 37. North America Parkinsons disease Drug Revenue by Country (2015-2020) (US\$ Million)

Table 38. North America Parkinsons disease Drug Revenue Market Share by Country (2015-2020)

Table 39. North America Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)

Table 40. North America Parkinsons disease Drug Sales Market Share by Type (2015-2020)

Table 41. North America Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)

Table 42. North America Parkinsons disease Drug Sales Market Share by Application (2015-2020)

Table 43. Europe Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)

Table 44. Europe Parkinsons disease Drug Sales Market Share by Country (2015-2020)

Table 45. Europe Parkinsons disease Drug Revenue by Country (2015-2020) (US\$ Million)

Table 46. Europe Parkinsons disease Drug Revenue Market Share by Country (2015-2020)

Table 47. Europe Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)

Table 48. Europe Parkinsons disease Drug Sales Market Share by Type (2015-2020)

Table 49. Europe Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)

Table 50. Europe Parkinsons disease Drug Sales Market Share by Application

(2015-2020)

Table 51. Asia Pacific Parkinsons disease Drug Sales by Region (2015-2020) (K Doses)

Table 52. Asia Pacific Parkinsons disease Drug Sales Market Share by Region (2015-2020)

Table 53. Asia Pacific Parkinsons disease Drug Revenue by Region (2015-2020) (US\$ Million)

Table 54. Asia Pacific Parkinsons disease Drug Revenue Market Share by Region (2015-2020)

Table 55. Asia Pacific Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)

Table 56. Asia Pacific Parkinsons disease Drug Sales Market Share by Type (2015-2020)

Table 57. Asia Pacific Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)

Table 58. Asia Pacific Parkinsons disease Drug Sales Market Share by Application (2015-2020)

Table 59. Latin America Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)

Table 60. Latin America Parkinsons disease Drug Sales Market Share by Country (2015-2020)

Table 61. Latin America Parkinsons disease Drug Revenue by Country (2015-2020) (US\$ Million)

Table 62. Latin America Parkinsons disease Drug Revenue Market Share by Country (2015-2020)

Table 63. Latin America Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)

Table 64. Latin America Parkinsons disease Drug Sales Market Share by Type (2015-2020)

Table 65. Latin America Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)

Table 66. Latin America Parkinsons disease Drug Sales Market Share by Application (2015-2020)

Table 67. Middle East and Africa Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)

Table 68. Middle East and Africa Parkinsons disease Drug Sales Market Share by Country (2015-2020)

Table 69. Middle East and Africa Parkinsons disease Drug Revenue by Country (2015-2020) (US\$ Million)

Table 70. Middle East and Africa Parkinsons disease Drug Revenue Market Share by

Country (2015-2020)

Table 71. Middle East and Africa Parkinsons disease Drug Sales by Type (2015-2020)  
(K Doses)

Table 72. Middle East and Africa Parkinsons disease Drug Sales Market Share by Type  
(2015-2020)

Table 73. Middle East and Africa Parkinsons disease Drug Sales by Application  
(2015-2020) (K Doses)

Table 74. Middle East and Africa Parkinsons disease Drug Sales Market Share by  
Application (2015-2020)

Table 75. Teva Corporation Information

Table 76. Teva Description and Major Businesses

Table 77. Teva Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million),  
Price (USD/Dose) and Gross Margin (2015-2020)

Table 78. Teva Product

Table 79. Teva Recent Development

Table 80. Novartis AG Corporation Information

Table 81. Novartis AG Description and Major Businesses

Table 82. Novartis AG Parkinsons disease Drug Production (K Doses), Revenue (US\$  
Million), Price (USD/Dose) and Gross Margin (2015-2020)

Table 83. Novartis AG Product

Table 84. Novartis AG Recent Development

Table 85. GSK Corporation Information

Table 86. GSK Description and Major Businesses

Table 87. GSK Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million),  
Price (USD/Dose) and Gross Margin (2015-2020)

Table 88. GSK Product

Table 89. GSK Recent Development

Table 90. AbbVie Corporation Information

Table 91. AbbVie Description and Major Businesses

Table 92. AbbVie Parkinsons disease Drug Production (K Doses), Revenue (US\$  
Million), Price (USD/Dose) and Gross Margin (2015-2020)

Table 93. AbbVie Product

Table 94. AbbVie Recent Development

Table 95. Merck Corporation Information

Table 96. Merck Description and Major Businesses

Table 97. Merck Parkinsons disease Drug Production (K Doses), Revenue (US\$  
Million), Price (USD/Dose) and Gross Margin (2015-2020)

Table 98. Merck Product

Table 99. Merck Recent Development

- Table 100. Boehringer Ingelheim Corporation Information
- Table 101. Boehringer Ingelheim Description and Major Businesses
- Table 102. Boehringer Ingelheim Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
- Table 103. Boehringer Ingelheim Product
- Table 104. Boehringer Ingelheim Recent Development
- Table 105. Impax Laboratories Corporation Information
- Table 106. Impax Laboratories Description and Major Businesses
- Table 107. Impax Laboratories Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
- Table 108. Impax Laboratories Product
- Table 109. Impax Laboratories Recent Development
- Table 110. Lundbeck Corporation Information
- Table 111. Lundbeck Description and Major Businesses
- Table 112. Lundbeck Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
- Table 113. Lundbeck Product
- Table 114. Lundbeck Recent Development
- Table 115. Sun Pharma Corporation Information
- Table 116. Sun Pharma Description and Major Businesses
- Table 117. Sun Pharma Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
- Table 118. Sun Pharma Product
- Table 119. Sun Pharma Recent Development
- Table 120. Wockhardt Corporation Information
- Table 121. Wockhardt Description and Major Businesses
- Table 122. Wockhardt Parkinsons disease Drug Production (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
- Table 123. Wockhardt Product
- Table 124. Wockhardt Recent Development
- Table 125. UCB Corporation Information
- Table 126. UCB Description and Major Businesses
- Table 127. UCB Parkinsons disease Drug Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
- Table 128. UCB Product
- Table 129. UCB Recent Development
- Table 130. Bausch Health Corporation Information
- Table 131. Bausch Health Description and Major Businesses
- Table 132. Bausch Health Parkinsons disease Drug Sales (K Doses), Revenue (US\$



Million), Price (USD/Dose) and Gross Margin (2015-2020)

Table 133. Bausch Health Product

Table 134. Bausch Health Recent Development

Table 135. Acadia Corporation Information

Table 136. Acadia Description and Major Businesses

Table 137. Acadia Parkinsons disease Drug Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2015-2020)

Table 138. Acadia Product

Table 139. Acadia Recent Development

Table 140. Global Parkinsons disease Drug Sales Forecast by Regions (2021-2026) (K Doses)

Table 141. Global Parkinsons disease Drug Sales Market Share Forecast by Regions (2021-2026)

Table 142. Global Parkinsons disease Drug Revenue Forecast by Regions (2021-2026) (US\$ Million)

Table 143. Global Parkinsons disease Drug Revenue Market Share Forecast by Regions (2021-2026)

Table 144. North America: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)

Table 145. North America: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 146. Europe: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)

Table 147. Europe: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 148. Asia Pacific: Parkinsons disease Drug Sales Forecast by Region (2021-2026) (K Doses)

Table 149. Asia Pacific: Parkinsons disease Drug Revenue Forecast by Region (2021-2026) (US\$ Million)

Table 150. Latin America: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)

Table 151. Latin America: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 152. Middle East and Africa: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)

Table 153. Middle East and Africa: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US\$ Million)

Table 154. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 155. Key Challenges

Table 156. Market Risks

Table 157. Main Points Interviewed from Key Parkinsons disease Drug Players

Table 158. Parkinsons disease Drug Customers List

Table 159. Parkinsons disease Drug Distributors List

Table 160. Research Programs/Design for This Report

Table 161. Key Data Information from Secondary Sources

Table 162. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

- Figure 1. Parkinsons disease Drug Product Picture
- Figure 2. Global Parkinsons disease Drug Sales Market Share by Type in 2020 & 2026
- Figure 3. Carbidopa/Levodopa Product Picture
- Figure 4. Dopamine Receptor Agonists Product Picture
- Figure 5. MAO-Inhibitors Product Picture
- Figure 6. Global Parkinsons disease Drug Sales Market Share by Application in 2020 & 2026
- Figure 7. Hospital
- Figure 8. Online
- Figure 9. Retail Pharmacies
- Figure 10. Parkinsons disease Drug Report Years Considered
- Figure 11. Global Parkinsons disease Drug Market Size 2015-2026 (US\$ Million)
- Figure 12. Global Parkinsons disease Drug Sales 2015-2026 (K Doses)
- Figure 13. Global Parkinsons disease Drug Market Size Market Share by Region: 2020 Versus 2026
- Figure 14. Global Parkinsons disease Drug Sales Market Share by Region (2015-2020)
- Figure 15. Global Parkinsons disease Drug Sales Market Share by Region in 2019
- Figure 16. Global Parkinsons disease Drug Revenue Market Share by Region (2015-2020)
- Figure 17. Global Parkinsons disease Drug Revenue Market Share by Region in 2019
- Figure 18. Global Parkinsons disease Drug Sales Share by Manufacturer in 2019
- Figure 19. The Top 10 and 5 Players Market Share by Parkinsons disease Drug Revenue in 2019
- Figure 20. Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
- Figure 21. Global Parkinsons disease Drug Sales Market Share by Type (2015-2020)
- Figure 22. Global Parkinsons disease Drug Sales Market Share by Type in 2019
- Figure 23. Global Parkinsons disease Drug Revenue Market Share by Type (2015-2020)
- Figure 24. Global Parkinsons disease Drug Revenue Market Share by Type in 2019
- Figure 25. Global Parkinsons disease Drug Market Share by Price Range (2015-2020)
- Figure 26. Global Parkinsons disease Drug Sales Market Share by Application (2015-2020)
- Figure 27. Global Parkinsons disease Drug Sales Market Share by Application in 2019
- Figure 28. Global Parkinsons disease Drug Revenue Market Share by Application

(2015-2020)

Figure 29. Global Parkinsons disease Drug Revenue Market Share by Application in 2019

Figure 30. North America Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)

Figure 31. North America Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 32. North America Parkinsons disease Drug Sales Market Share by Country in 2019

Figure 33. North America Parkinsons disease Drug Revenue Market Share by Country in 2019

Figure 34. U.S. Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 35. U.S. Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 36. Canada Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 37. Canada Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 38. North America Parkinsons disease Drug Market Share by Type in 2019

Figure 39. North America Parkinsons disease Drug Market Share by Application in 2019

Figure 40. Europe Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)

Figure 41. Europe Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 42. Europe Parkinsons disease Drug Sales Market Share by Country in 2019

Figure 43. Europe Parkinsons disease Drug Revenue Market Share by Country in 2019

Figure 44. Germany Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 45. Germany Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 46. France Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 47. France Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 48. U.K. Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 49. U.K. Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 50. Italy Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 51. Italy Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 52. Russia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 53. Russia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$

Million)

Figure 54. Europe Parkinsons disease Drug Market Share by Type in 2019

Figure 55. Europe Parkinsons disease Drug Market Share by Application in 2019

Figure 56. Asia Pacific Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)

Figure 57. Asia Pacific Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 58. Asia Pacific Parkinsons disease Drug Sales Market Share by Region in 2019

Figure 59. Asia Pacific Parkinsons disease Drug Revenue Market Share by Region in 2019

Figure 60. China Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 61. China Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 62. Japan Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 63. Japan Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 64. South Korea Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 65. South Korea Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 66. India Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 67. India Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 68. Australia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 69. Australia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 70. Taiwan Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 71. Taiwan Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 72. Indonesia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 73. Indonesia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 74. Thailand Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 75. Thailand Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 76. Malaysia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K

Doses)

Figure 77. Malaysia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 78. Philippines Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 79. Philippines Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 80. Vietnam Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 81. Vietnam Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 82. Asia Pacific Parkinsons disease Drug Market Share by Type in 2019

Figure 83. Asia Pacific Parkinsons disease Drug Market Share by Application in 2019

Figure 84. Latin America Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)

Figure 85. Latin America Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 86. Latin America Parkinsons disease Drug Sales Market Share by Country in 2019

Figure 87. Latin America Parkinsons disease Drug Revenue Market Share by Country in 2019

Figure 88. Mexico Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 89. Mexico Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 90. Brazil Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 91. Brazil Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 92. Argentina Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 93. Argentina Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 94. Latin America Parkinsons disease Drug Market Share by Type in 2019

Figure 95. Latin America Parkinsons disease Drug Market Share by Application in 2019

Figure 96. Middle East and Africa Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)

Figure 97. Middle East and Africa Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 98. Middle East and Africa Parkinsons disease Drug Sales Market Share by Country in 2019

Figure 99. Middle East and Africa Parkinsons disease Drug Revenue Market Share by

Country in 2019

Figure 100. Turkey Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 101. Turkey Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 102. Saudi Arabia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 103. Saudi Arabia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 104. U.A.E Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)

Figure 105. U.A.E Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 106. Middle East and Africa Parkinsons disease Drug Market Share by Type in 2019

Figure 107. Middle East and Africa Parkinsons disease Drug Market Share by Application in 2019

Figure 108. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 109. Novartis AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 110. GSK Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 111. AbbVie Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 112. Merck Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 113. Boehringer Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 114. Impax Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 115. Lundbeck Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 116. Sun Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 117. Wockhardt Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 118. UCB Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 119. Bausch Health Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 120. Acadia Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 121. North America Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)

Figure 122. North America Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 123. Europe Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)

Figure 124. Europe Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 125. Asia Pacific Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)

Figure 126. Asia Pacific Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 127. Latin America Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)

Figure 128. Latin America Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 129. Middle East and Africa Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)

Figure 130. Middle East and Africa Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 131. Porter's Five Forces Analysis

Figure 132. Channels of Distribution

Figure 133. Distributors Profiles

Figure 134. Bottom-up and Top-down Approaches for This Report

Figure 135. Data Triangulation

Figure 136. Key Executives Interviewed



## I would like to order

Product name: COVID-19 Impact on Global Parkinsons disease Drug Market Insights, Forecast to 2026

Product link: <https://marketpublishers.com/r/CBA090596847EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CBA090596847EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970